OBJECTIVE: To assess the effectiveness and safety of antiretrovirals (ARVs) used for treatment or prophylaxis in a breastfeeding population of HIV-1-infected women (Burkina-Faso, Kenya, South Africa). METHODS: HIV-1-infected pregnant women with <200 CD4 cells per cubic millimeter or with World Health Organization stage 4 disease (cohort A) and asymptomatic women with >500 CD4 cells per cubic millimeter (cohort B) were enrolled into 2 prospective cohorts. Women with 200-500 CD4 cells per cubic millimeter were enrolled in a parallel randomized trial. Women in cohort A initiated antiretroviral therapy. Women in cohort B received zidovudine from 34 to 36 weeks gestation until delivery, with single-dose nevirapine in labor (cohort B). All children received single-dose nevirapine. RESULTS: Of 248 women enrolled, 111 (cohort A) and 125 (cohort B) infants alive at 24 hours after birth were analyzed. Sixty-nine percent and 42% of women had undetectable viral load at delivery, respectively. Ten children in each cohort died. The 18-month cumulative incidences of HIV-1 infection were 7.5% (95% confidence interval: 3.8% to 14.5%) (cohort A) and 5.8% (2.8% to 11.8%) (cohort B). Sixty-one percent (cohort A) and 78% (cohort B) were breastfed for a median duration of 20 weeks. Four children in cohort A and only 1 in cohort B became HIV-1 infected after 6 weeks of age. CONCLUSIONS: Antiretroviral therapy initiated a median of 7 weeks before delivery in women with advanced HIV-1 disease was associated with a significant residual risk of HIV-1 transmission due to insufficient decrease in viral load by the time of delivery. Among women with >500 CD4 cells per cubic millimeter, the risk of breast-milk transmission was very low despite lack of postnatal prophylaxis.
RCT Entities:
OBJECTIVE: To assess the effectiveness and safety of antiretrovirals (ARVs) used for treatment or prophylaxis in a breastfeeding population of HIV-1-infectedwomen (Burkina-Faso, Kenya, South Africa). METHODS:HIV-1-infected pregnant women with <200 CD4 cells per cubic millimeter or with World Health Organization stage 4 disease (cohort A) and asymptomatic women with >500 CD4 cells per cubic millimeter (cohort B) were enrolled into 2 prospective cohorts. Women with 200-500 CD4 cells per cubic millimeter were enrolled in a parallel randomized trial. Women in cohort A initiated antiretroviral therapy. Women in cohort B received zidovudine from 34 to 36 weeks gestation until delivery, with single-dose nevirapine in labor (cohort B). All children received single-dose nevirapine. RESULTS: Of 248 women enrolled, 111 (cohort A) and 125 (cohort B) infants alive at 24 hours after birth were analyzed. Sixty-nine percent and 42% of women had undetectable viral load at delivery, respectively. Ten children in each cohort died. The 18-month cumulative incidences of HIV-1 infection were 7.5% (95% confidence interval: 3.8% to 14.5%) (cohort A) and 5.8% (2.8% to 11.8%) (cohort B). Sixty-one percent (cohort A) and 78% (cohort B) were breastfed for a median duration of 20 weeks. Four children in cohort A and only 1 in cohort B became HIV-1 infected after 6 weeks of age. CONCLUSIONS: Antiretroviral therapy initiated a median of 7 weeks before delivery in women with advanced HIV-1 disease was associated with a significant residual risk of HIV-1 transmission due to insufficient decrease in viral load by the time of delivery. Among women with >500 CD4 cells per cubic millimeter, the risk of breast-milk transmission was very low despite lack of postnatal prophylaxis.
Authors: Alexandra Coria; Francine Noel; Jerry Bonhomme; Vanessa Rouzier; Christian Perodin; Adias Marcelin; Zhongze Li; Tor D Tosteson; Marie-Marcelle Deschamps; Peter F Wright; Jean W Pape Journal: J Acquir Immune Defic Syndr Date: 2012-12-15 Impact factor: 3.731
Authors: Andrea L Ciaranello; Valeriane Leroy; Asinath Rusibamayila; Kenneth A Freedberg; Roger Shapiro; Barbara Engelsmann; Shahin Lockman; Kathleen A Kelly; François Dabis; Rochelle P Walensky Journal: AIDS Date: 2014-07 Impact factor: 4.177
Authors: Sera L Young; Mduduzi N N Mbuya; Caroline J Chantry; Eveline P Geubbels; Kiersten Israel-Ballard; Deborah Cohan; Stephen A Vosti; Michael C Latham Journal: Adv Nutr Date: 2011-04-30 Impact factor: 8.701
Authors: Jean B Nachega; Olalekan A Uthman; Jean Anderson; Karl Peltzer; Sarah Wampold; Mark F Cotton; Edward J Mills; Yuh-Shan Ho; Jeffrey S A Stringer; James A McIntyre; Lynne M Mofenson Journal: AIDS Date: 2012-10-23 Impact factor: 4.177
Authors: Andrea L Ciaranello; Freddy Perez; Matthews Maruva; Jennifer Chu; Barbara Engelsmann; Jo Keatinge; Rochelle P Walensky; Angela Mushavi; Rumbidzai Mugwagwa; Francois Dabis; Kenneth A Freedberg Journal: PLoS One Date: 2011-06-02 Impact factor: 3.240
Authors: Paul Ayuo; Beverly Musick; Hai Liu; Paula Braitstein; Winstone Nyandiko; Boaz Otieno-Nyunya; Adrian Gardner; Kara Wools-Kaloustian Journal: J Int AIDS Soc Date: 2013-01-02 Impact factor: 5.396